Cancer RadiotherapiePub Date : 2026-11-01Epub Date: 2026-11-13DOI: 10.1016/j.canrad.2026.104884
Clara Naessens, Nicolas Giraud, Sarah Adgie, Judith Lego, Alexandre Dutoit, Jean-Frédéric Blanc, Véronique Vendrely
{"title":"Patterns of recurrence after stereotactic ablative radiotherapy for hepatocellular carcinoma: A monocentric retrospective analysis","authors":"Clara Naessens, Nicolas Giraud, Sarah Adgie, Judith Lego, Alexandre Dutoit, Jean-Frédéric Blanc, Véronique Vendrely","doi":"10.1016/j.canrad.2026.104884","DOIUrl":"10.1016/j.canrad.2026.104884","url":null,"abstract":"<div><h3>Introduction</h3><div>Stereotactic ablative radiotherapy is an option for the treatment of early-stage hepatocellular carcinoma. However, there is a scarcity of data investigating hepatic recurrence patterns, i.e. the location of recurrences in relation to radiation fields. The purpose of this study, was to characterise intrahepatic recurrence of hepatocellular carcinoma after stereotactic ablative radiotherapy, and to report survival outcomes and treatment tolerance.</div></div><div><h3>Materials and methods</h3><div>We included patients with one to two unresectable, localised hepatocellular carcinoma lesions who were not eligible for percutaneous ablation, with Child-Pugh class A to B7 liver function and <!--> <!--> <!-->performance status up to 2 according to the Eastern Cooperative Oncology Group. Hepatic recurrences were analyzed by fusing the planning computed tomography with recurrence imaging to study the relationship between the planning target volume and the recurrence centroid. Local recurrence was defined as “in-field” if the centroid touched or crossed the <!--> <!--> <!--> <!-->planning target volume, “marginal” if within up to 1 cm, or “out-of-field” otherwise. Secondary endpoints included hepatic progression-free-survival, overall survival, risk factors for progression-free survival, and toxicity.</div></div><div><h3>Results</h3><div>Between 2016 and 2023, 64 consecutive patients (70 lesions) were treated with a median dose of 45<!--> <!-->Gy in three fractions to the 80 % isodose line. Forty-eight patients had received prior local treatment for hepatocellular carcinoma, and 32 had received treatment of the irradiated nodule. Over a median follow-up of 28 months, the intrahepatic recurrence rate was 40.6 %, with 80.9 % occurring out-of-field, 19.2 % marginal, and none in-field. The median hepatic progression-free survival was 14 months (95 % confidence interval: 1–26 months), and the median overall survival was 33 months (95 % confidence interval: 5–42 months). No progression-free survival risk factors were identified.</div></div><div><h3>Conclusion</h3><div>Stereotactic ablative radiotherapy provides excellent in-field local control for localized hepatocellular carcinoma. Future studies should harmonise intrahepatic control definitions using field-based approaches.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 7","pages":"Article 104884"},"PeriodicalIF":1.3,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149399130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer RadiotherapiePub Date : 2026-11-01Epub Date: 2026-11-13DOI: 10.1016/j.canrad.2026.104885
Jarno Bouveret, Vincent Fave, David Benzaquen, Daniel Taussky, Ambroise Champion
{"title":"Case series of adaptive pelvic radiotherapy using ETHOS: Lessons from two clinical examples","authors":"Jarno Bouveret, Vincent Fave, David Benzaquen, Daniel Taussky, Ambroise Champion","doi":"10.1016/j.canrad.2026.104885","DOIUrl":"10.1016/j.canrad.2026.104885","url":null,"abstract":"<div><div>This technical note presents two illustrative clinical cases encountered during the implementation of pelvic adaptive radiotherapy using the ETHOS system. Each example highlights a specific phenomenon observed during daily adaptive treatments: substantial increases in monitor units when rectum – planning target volumes spacing decreases, hotspots outside the target due to shifting optimization priorities. For each case, practical corrective actions were introduced, including trimmed organs at risk – derived structures and dedicated planning target volume rings. These examples demonstrate how iterative template refinement and workflow adjustments can stabilize optimization and enhance daily safety. Overall, the case series underscores the educational value of real-world examples for centers beginning or refining their ETHOS-based adaptive radiotherapy programs.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 7","pages":"Article 104885"},"PeriodicalIF":1.3,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149399135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer RadiotherapiePub Date : 2026-11-01Epub Date: 2026-11-13DOI: 10.1016/j.canrad.2026.104882
Vincent Laiman, Torana Kurniawan, Ericko Ekaputra, Lidya Meidania, Wigati Dhamiyati, Sri Retna Dwidanarti, Seize Edwiena Yanuarta
{"title":"Combined excision and radiation therapy for keloid management: A systematic review","authors":"Vincent Laiman, Torana Kurniawan, Ericko Ekaputra, Lidya Meidania, Wigati Dhamiyati, Sri Retna Dwidanarti, Seize Edwiena Yanuarta","doi":"10.1016/j.canrad.2026.104882","DOIUrl":"10.1016/j.canrad.2026.104882","url":null,"abstract":"<div><h3>Background</h3><div>Keloids are fibroproliferative disorders that pose therapeutic challenges due to their high recurrence rates, pain, and discomfort. However, the efficacy between different therapeutic modalities, particularly radiation therapy remains unclear. This systematic review aimed to compare the combination of excision and radiation therapy with other modalities.</div></div><div><h3>Method</h3><div>A systematic literature search from PubMed, Cochrane, and Web of Science was performed in December 2024. Search strategies with keywords related to “keloid”, “radiation therapy”, “treatment”, and “outcome” were performed. Search was limited to prospective clinical trials that compared excision combined with radiation therapy to other keloid treatment modalities.</div></div><div><h3>Results</h3><div>A total of 723 studies were screened and six were included which reported 375 patients with a total of 427 lesions. Radiation therapy doses ranged from 0.8 Gy to 18 Gy, with fractions ranging from one to four. Postoperative irradiation was delivered on the same day or within 48 hours postoperatively. Excision combined with radiation therapy demonstrated higher complete response rates and better pain resolution compared to cryotherapy with triamcinolone acetonide, cryotherapy alone, and betamethasone with 5-fluorouracil, with or without excision. Hyperpigmentation was more commonly reported with excision and radiation therapy, while hypopigmentation was more frequent with other treatments. Studies with patient satisfaction data reported higher satisfaction after combination of excision and radiation therapy compared to other modalities.</div></div><div><h3>Conclusion</h3><div>Excision combined with radiation therapy showed superior outcome compared to other modalities, particularly cryotherapy-based treatment, with higher pain resolution, and patient satisfaction. Notably, brachytherapy yielded the most favorable results in keloid treatment, with earlier postoperative irradiation suggestive of better control.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 7","pages":"Article 104882"},"PeriodicalIF":1.3,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149399134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer RadiotherapiePub Date : 2026-08-01Epub Date: 2026-10-26DOI: 10.1016/j.canrad.2026.104899
Jérôme Doyen, Syrine Ben Dhia
{"title":"Radiotherapy for skin tumors and soft-tissue sarcomas: Current state of the art and recent advances","authors":"Jérôme Doyen, Syrine Ben Dhia","doi":"10.1016/j.canrad.2026.104899","DOIUrl":"10.1016/j.canrad.2026.104899","url":null,"abstract":"<div><div>Radiotherapy plays a pivotal role in the management of skin cancers and soft-tissue sarcomas in both curative and adjuvant settings. Over recent years, several clinical trials and international guidelines have refined its indications and identified new strategies that are likely to influence clinical practice. This review provides an updated overview of the role of radiotherapy in basal cell carcinoma, cutaneous squamous cell carcinoma, cutaneous melanoma, Merkel cell carcinoma, cutaneous lymphoma, and soft-tissue sarcoma. Recent evidence highlights the potential benefit of consolidation radiotherapy following hedgehog inhibitors in locally advanced basal cell carcinoma, improved outcomes with the combination of cemiplimab and radiotherapy in cutaneous squamous cell carcinoma, integration of stereotactic radiotherapy with immune checkpoint inhibitors for melanoma brain metastases, the importance of minimizing the interval between surgery and postoperative radiotherapy in Merkel cell carcinoma, the limitations of ultra-low-dose radiotherapy for indolent cutaneous lymphomas, and the emergence of hypofractionated preoperative radiotherapy schedules for soft-tissue sarcoma. By distinguishing established indications from emerging evidence, this review summarizes the developments most likely to influence contemporary radiation oncology practice and highlights areas where further prospective studies are warranted.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 5","pages":"Article 104899"},"PeriodicalIF":1.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149257908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer RadiotherapiePub Date : 2026-08-01Epub Date: 2026-10-26DOI: 10.1016/j.canrad.2026.104900
Constance Huck, Claire Zobouyan, Géraldine Pignot, Gautier Marcq, Mathieu Roumiguie, David Pasquier, Samir Achkar, Jonathan Khalifa, Paul Sargos
{"title":"Postoperative radiotherapy after radical cystectomy for muscle-invasive bladder cancer: Patient selection, target delineation and contemporary evidence","authors":"Constance Huck, Claire Zobouyan, Géraldine Pignot, Gautier Marcq, Mathieu Roumiguie, David Pasquier, Samir Achkar, Jonathan Khalifa, Paul Sargos","doi":"10.1016/j.canrad.2026.104900","DOIUrl":"10.1016/j.canrad.2026.104900","url":null,"abstract":"<div><div>Following radical cystectomy, muscle-invasive bladder cancer remains associated with a substantial risk of locoregional recurrence, particularly in patients with pT3–4 disease, nodal involvement, positive surgical margins, or limited pelvic lymph node dissection. Historically, adjuvant radiotherapy reduced pelvic recurrence rates but was largely abandoned because of toxicity concerns associated with older radiation techniques. The development of intensity-modulated radiotherapy, image-guided radiotherapy, contemporary contouring guidelines, and modern dose constraints has renewed interest in adjuvant radiotherapy. Recent randomized trials, including Bladder-ART/GETUG-AFU30 and BART, have demonstrated that modern adjuvant radiotherapy can be safely delivered and significantly improve locoregional control in selected high-risk patients. Current International Bladder Investigator Society recommendations have standardized target volume delineation, including pelvic nodal regions and cystectomy bed. At the same time, the management of muscle-invasive bladder cancer is rapidly evolving with the integration of immune checkpoint inhibitors, antibody–drug conjugates and circulating tumor DNA-guided based treatment strategies. Future research should focus on refining patient selection and integrating adjuvant radiotherapy within a personalized multimodal approach combining clinicopathological risk factors, molecular biomarkers, and contemporary systemic therapies.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 5","pages":"Article 104900"},"PeriodicalIF":1.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149257915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"It is a good analysis when…: Quality criteria for a reactive analysis following an adverse event","authors":"Gianfranco Brusadin, Margaux Charpentier, Mathieu Herbez, Stéphanie Crombet","doi":"10.1016/j.canrad.2026.104893","DOIUrl":"10.1016/j.canrad.2026.104893","url":null,"abstract":"<div><h3>Objective</h3><div>Although radiation oncology relies heavily on adverse event reporting to improve patient safety, the quality of retrospective analyses remains heterogeneous, often leading to ineffective action plans (retraining, simple reminders to remain vigilant). This article aims to propose criteria defining a high-quality reactive analysis based on the human, social, and organizational factors that determine its effectiveness, regardless of the investigation methodology used (ALARM, ORION, etc.).</div></div><div><h3>Discussion</h3><div>Conducting an effective analysis requires, above all, a non-punitive “just culture” and impartial leadership by an expert trained in cognitive biases. The analysis process is broken down into three key steps: an objective and immediate gathering of facts by a neutral person; a multidisciplinary analysis meeting focused on systemic failures rather than individual blame, dedicating most of its time to developing robust corrective actions; and finally, monitoring the deployment. Furthermore, evaluating the effectiveness of these actions cannot be reduced to the simple absence of recurrence, particularly for rare events, and requires the implementation of proactive approaches such as targeted audits or unannounced “stress tests”.</div></div><div><h3>Conclusion</h3><div>Ultimately, the value of an analysis depends more on the rigor and fairness with which it is conducted than on the specific tool selected. To sustainably improve safety, it is essential to move beyond technological performance alone and embed collective learning and patient safety within the organization's culture and identity. Direct integration of patients into these analytical processes represents the next challenge in advancing shared systemic resilience.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 5","pages":"Article 104893"},"PeriodicalIF":1.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149257690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer RadiotherapiePub Date : 2026-08-01Epub Date: 2026-10-26DOI: 10.1016/j.canrad.2026.104890
Adnan Antoine Shrebati, Florence Huguet, Malik Nebbache, Camille Tlemsani, Lucie Houdou, Oliver Chapet, Fabrice Lorchel, Jeanne Duval, Clément Grosnon, Audrey Larnaudie, Emma Ferber, Martin Duval, Charles Raynaud
{"title":"Professional insertion of young French oncologists after post-residency fellowship: A national declarative survey","authors":"Adnan Antoine Shrebati, Florence Huguet, Malik Nebbache, Camille Tlemsani, Lucie Houdou, Oliver Chapet, Fabrice Lorchel, Jeanne Duval, Clément Grosnon, Audrey Larnaudie, Emma Ferber, Martin Duval, Charles Raynaud","doi":"10.1016/j.canrad.2026.104890","DOIUrl":"10.1016/j.canrad.2026.104890","url":null,"abstract":"<div><h3>Purpose</h3><div>The purpose of this study was to describe the career paths of young French medical oncologists and radiation oncologists after post-residency fellowship and to quantify professional insertion difficulty, its associated factors and reported impact. This was a national cross-sectional declarative survey.</div></div><div><h3>Materials and methods</h3><div>A self-administered online questionnaire was distributed from 22nd May to 9th June 2026, through professional networks, to oncologists who had completed their residency and/or post-residency fellowship between November 2021 and November 2025. Insertion difficulty was defined a priori by a composite criterion (at least one of: job search of one year or more, constrained locum work, constrained part-time work, constrained change of region, or no oncologist position). The inserted cohort comprised respondents who had completed their post-residency fellowship. Comparisons used Fisher exact, chi-squared and Mann-Whitney tests, with logistic regression for trends.</div></div><div><h3>Results</h3><div>Among 142 respondents (97radiation oncologists, 45 medical oncologists; 76 women; median age 32.5 years), 98 (69 %) were inserted. Twenty-seven (27.6 %) met the composite criterion, reaching 34.7 % in sensitivity analysis. Difficulty was markedly higher in radiation oncologists than medical oncologists (36.8 versus 6.7 %; odds ratio 8.14, 95 % confidence interval: 1.79–37.10; <em>p</em> <!-->=<!--> <!-->0.0026) and inversely associated with parenthood (odds ratio: 0.37; <em>p</em> <!-->=<!--> <!-->0.042). It was accompanied by lower income and overall satisfaction (<em>p</em> <!-->=<!--> <!-->0.0045 and <em>p</em> <!-->=<!--> <!-->0.0001) and a threefold more frequent five-year intention to change position (<em>p</em> <!-->=<!--> <!-->0.0003).</div></div><div><h3>Conclusion</h3><div>More than one quarter of young French oncologists reported an objectifiable insertion difficulty after post-residency fellowship, predominantly in radiation oncology, warranting prospective monitoring of training-to-job adequacy.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 5","pages":"Article 104890"},"PeriodicalIF":1.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149257691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer RadiotherapiePub Date : 2026-08-01Epub Date: 2026-10-26DOI: 10.1016/j.canrad.2026.104895
Constance Huck, Géraldine Pignot, Alexandra Masson-Lecomte, David Pasquier, Vérane Achard
{"title":"Quality of life after trimodal treatment for muscle-invasive bladder cancer","authors":"Constance Huck, Géraldine Pignot, Alexandra Masson-Lecomte, David Pasquier, Vérane Achard","doi":"10.1016/j.canrad.2026.104895","DOIUrl":"10.1016/j.canrad.2026.104895","url":null,"abstract":"<div><div>Muscle-invasive bladder cancer has traditionally been treated with radical cystectomy and pelvic lymph node dissection. However, trimodality treatment, consisting of maximal transurethral resection of the bladder tumour followed by radiotherapy with concurrent radiosensitisation, has emerged as an effective bladder-preserving alternative for selected patients. As oncological outcomes after trimodality treatment appear comparable to those of radical cystectomy in appropriately selected patients, quality of life has become a key consideration in treatment selection. This review summarizes the current evidence regarding quality of life after trimodality treatment and compares these outcomes with those reported after radical cystectomy. We discuss the principal patient-reported outcome measures used in bladder cancer and review data on urinary, bowel, sexual, and global health-related quality of life following both treatment approaches. Available evidence indicates that quality of life after trimodality treatment typically declines during treatment but recovers to baseline within approximately six months in most patients. Long-term survivors generally maintain satisfactory urinary and bowel function and good overall quality of life. Comparative prospective studies suggest similar overall health-related quality of life between trimodality treatment and radical cystectomy, with bladder preservation offering advantages in body image and sexual function. Although current evidence is limited by heterogeneous study designs, quality of life should be considered alongside oncological outcomes when counselling patients with muscle invasive bladder cancer. Future prospective studies using standardized patient-reported outcome measures and longer follow-up are needed to further refine treatment decision-making.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 5","pages":"Article 104895"},"PeriodicalIF":1.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149257914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Dose accumulation in reirradiation: Key practical considerations","authors":"Myriam Ayadi, Magali Sandt, Justine Deborne, Marie-Pierre Sunyach, Pauline Dupuis","doi":"10.1016/j.canrad.2026.104901","DOIUrl":"10.1016/j.canrad.2026.104901","url":null,"abstract":"<div><div>Reirradiation is a challenge due to both clinical and technical considerations. Dose accumulation corresponds to the summation between previous and current treatment dose distribution and is fundamental to guide clinical decision-making as it helps to estimate cumulative dose to organs of interest and ensure that they comply with institutional or literature-based dose constraints. Performing dose accumulation must rely on a rigorous process, depending on the data available regarding previous irradiation and the tools available in the clinic. In this paper, we present and discuss the different dose accumulation methods, their degree of complexity and potential limitations.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 5","pages":"Article 104901"},"PeriodicalIF":1.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149257918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer RadiotherapiePub Date : 2026-08-01Epub Date: 2026-10-26DOI: 10.1016/j.canrad.2026.104889
François Lucia, Laura Deiana, Pierre-François Dupré, Cyrus Chargari
{"title":"Stereotactic body radiotherapy for oligometastatic ovarian cancer: Current evidence, patient selection, and future directions","authors":"François Lucia, Laura Deiana, Pierre-François Dupré, Cyrus Chargari","doi":"10.1016/j.canrad.2026.104889","DOIUrl":"10.1016/j.canrad.2026.104889","url":null,"abstract":"<div><div>Ovarian cancer recurs in a limited number of sites in a significant proportion of patients, raising interest in metastasis-directed therapy to delay systemic treatment escalation. Stereotactic body radiotherapy is increasingly used in this context. This review synthesises the available evidence on the role of stereotactic body radiotherapy in oligometastatic ovarian cancer, with emphasis on prospective data, patient selection criteria, integration with systemic therapies, and emerging technological approaches. The phase II trial MITO-RT3/RAD, first prospective, multicentre study in this setting reported excellent results in terms of complete response rates and local control at 12 months, with complete response emerging as a strong predictor of local control. The treatment was also very well tolerated, with no grade<!--> <!--> <!-->3 or worse toxicity and a low rate of grade 1–2 toxicity. Stereotactic body radiotherapy is a safe, effective metastasis-directed therapy option endorsed by current European guidelines. Key unresolved questions include the optimal integration with poly (ADP-ribose) polymerase inhibitors, the surgery versus stereotactic body radiotherapy comparison, and the management of peritoneal oligometastatic disease. The randomised ENGOT-ov74/LoRiO trial will address several of these gaps.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 5","pages":"Article 104889"},"PeriodicalIF":1.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149257684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}